News and Releases | Mexican Pharmacy | EyegatePharma.com

EyeGate Pharma Receives USPTO Notice Of Allowance For Next Generation Of Proprietary Iontophoretic Delivery System

Patent to Provide Broad Coverage for EyeGate II® Delivery System with Pre-filled Drug Applicator Also, Patent Covering Proprietary Dexamethasone Phosphate Pharmaceutical Formulation Granted WALTHAM, Mass., Oct. 15, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases…

July 3, 2023adminPress Releases

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

Patent to Provide Broad Coverage for Steroid Delivered Via Ocular Iontophoresis WALTHAM, Mass., July 24, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc.(OTCQB:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has received a…

July 3, 2023adminPress Releases

EyeGate Pharma Regains Nasdaq Listing Compliance

WALTHAM, Mass., Sept. 23, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the Company has regained compliance with Nasdaq Listing Rule 5550 (a)(2), which concerns minimum bid price listing requirements. “We are pleased to be…

July 3, 2023adminPress Releases

EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, May 8, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the quarter ended March 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “During the first quarter of 2019, we continued to execute on our…

July 3, 2023adminPress Releases

EyeGate Pharma Enrolls First Patient In Confirmatory Phase 3 Clinical Trial EGP-437-006 For Non-Infectious Anterior Uveitis

Data Anticipated Q1 2017 WALTHAM, Mass., Jan. 19, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that the first patient was enrolled in the Company’s confirmatory Phase 3 clinical trial…

July 3, 2023adminPress Releases

EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the first patient in its follow-on pilot study for punctate epitheliopathies (“PE”). The study will use the Ocular Bandage Gel…

July 3, 2023adminPress Releases

EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study

WALTHAM, MA, November 22, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received select topline data, specifically the primary endpoint, demonstrating superiority over standard-of-care in its corneal wound repair pivotal study using the…

July 3, 2023adminPress Releases

EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study

WALTHAM, Mass., August 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 50% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…

July 3, 2023adminPress Releases

EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

WALTHAM, Mass., Sept. 16, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 75% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…

July 3, 2023adminPress Releases

EyeGate Pharma Receives $1.9 Million From Exercised Warrants

WALTHAM, MA, December 17, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive topline data on November 22, 2019 for its pivotal corneal wound repair study. The Company is currently evaluating several…

July 3, 2023adminPress Releases

Category: News and Releases